The development of the synthetic acyclic purine nucleoside analog acyclovir was a milestone in the field of antiviral chemotherapy. Acyclovir possesses unique biologic properties that make it especially useful for the treatment of herpesvirus infections. This article presents guidelines for the use of acyclovir in both immunocompetent and immunocompromised patients. The problem of acyclovir resistance is also discussed.